Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Revenue Growth Forecast To Reach $91.73 Billion By 2030 At 9.5% CAGR
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Changes In Market Value Are Expected For The Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Over The 2026–2030 Period?
The market for vascular endothelial growth factor (VEGF) inhibitors has experienced significant expansion recently. This market is projected to expand from $11.3 billion in 2025 to $12.11 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.2%. Historically, this growth can be ascribed to several factors, including the increasing occurrence of cancer and retinal conditions, the scarcity of treatment alternatives prior to monoclonal antibodies, a heightened understanding of the advantages of anti-angiogenic therapy, greater acceptance of targeted therapies by medical professionals, and the regulatory clearances of initial VEGF inhibitors.
The vascular endothelial growth factor (vegf) inhibitor market size is expected to show significant expansion in the coming years. It is projected to achieve $16.23 billion by 2030, progressing at a compound annual growth rate (CAGR) of 7.6%. The anticipated growth during this period stems from factors such as the creation of next-generation vegf inhibitors, the broadening of immuno-oncology combinations, the increased embrace of personalized medicine, growing investments in ophthalmic drug development, and the incorporation of digital monitoring alongside AI-based treatment assessment. Prominent trends expected in the forecast period involve a rising uptake of vegf inhibitors in both oncology and ophthalmology, an increase in the development of monoclonal antibodies and anti-angiogenic therapies, the expansion of intravitreal and intravenous administration routes, the proliferation of personalized medicine and targeted therapy approaches, and a surge in clinical trials and research for novel vegf inhibitors.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3437&type=smp
Which Key Factors Are Driving The Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Growth?
The increasing occurrence of cancer and macular degeneration is projected to drive the expansion of the VEGF inhibitor market in the future. Cancer involves the unchecked proliferation of abnormal cells, which can spread throughout the body, whereas macular degeneration is a health issue causing the central part of the retina to degrade, impairing sight. This escalation in these conditions’ prevalence is driven by elements like an aging demographic and lifestyle-associated dangers, consequently boosting the need for efficacious treatments and medical interventions. Vascular endothelial growth factor (VEGF) Inhibitors contribute to fighting cancer by hindering the development of new blood vessels essential for tumor proliferation and dissemination, thus curbing tumor expansion and metastasis. For example, in February 2024, the World Health Organization, an international body based in Switzerland focused on global health policy and public health endeavors, forecasted more than 35 million new cancer cases by 2050, representing a 77% rise from the approximately 20 million cases in 2022. Consequently, the expanding occurrence of cancer and macular degeneration is propelling the growth of the VEGF inhibitor market.
How Is The Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Organized By Segment Classification?
The vascular endothelial growth factor (vegf) inhibitor market covered in this report is segmented –
1) By Drugs Type: Avastin, Tecentriq, Lucentis, Cometriq, Eylea, Other Drug Types
2) By Route Of Administration: Oral, Intravenous, Intravitreal
3) By Application: Oncology, Ophthalmology, Other Applications
Subsegments:
1) By Avastin: Oncology Applications, Ophthalmology Applications
2) By Tecentriq: Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Bladder Cancer, Triple-Negative Breast Cancer
3) By Lucentis: Wet Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, Retinal Vein Occlusion
4) By Cometriq: Medullary Thyroid Cancer, Renal Cell Carcinoma
5) By Eylea: Wet Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)
6) By Other Drug Types: Immuno-Oncology Drugs, Anti-Angiogenic Agents, Other Monoclonal Antibodies
Which Trends Are Shaping Growth In The Vascular Endothelial Growth Factor (VEGF) Inhibitor Market?
Major companies in the VEGF inhibitor market are prioritizing the creation of advanced ophthalmic treatments, specifically higher-concentration intravitreal injection solutions, to extend dosing intervals and reduce the overall treatment burden for patients. These solutions are eye medications containing an increased amount of active drug per dose, which helps decrease the frequency of injections while maintaining effectiveness and easing the patient’s treatment load. For example, in April 2024, Santen Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, partnered with Bayer Yakuhin, another Japan-based pharmaceutical and life sciences company, to launch the Ophthalmic VEGF Inhibitor Eylea 8mg Solution for Intravitreal Injection 114.3 mg/mL. These are standard therapies for conditions such as age-related macular degeneration (nAMD) and diabetic macular edema (DME), which can lead to blindness. Eylea 8mg, being more concentrated than its predecessor, offers a longer dosing interval of up to 16 weeks, thereby reducing the number of intravitreal injections required while ensuring efficacy and safety. This innovation aims to alleviate the treatment burden on patients and establish a new benchmark for care, representing a strategic collaboration designed to broaden the availability and reach of this pioneering ophthalmic treatment.
Who Are The Industry Participants Involved In The Vascular Endothelial Growth Factor (VEGF) Inhibitor Market?
Major companies operating in the vascular endothelial growth factor (vegf) inhibitor market are F. Hoffmann-La Roche AG, Bayer AG, Regeneron Pharmaceuticals Inc., AstraZeneca Plc., Novartis AG, Pfizer Inc., Eli Lilly and Company, Exelixis Inc., Amgen Inc., Sanofi S.A., Cipla Limited, Biocon, Dr. Reddy’s Laboratories, Innovent Biologics, Daiichi Sankyo, Chugai Pharmaceutical Co. Ltd, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Ipsen, Oxurion, Pharmstandard Group, Zentiva, Coherus BioSciences Inc., AVEO pharmaceuticals, Eisai Co. Ltd.
Get The Full Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Report:
Where Is The Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Primarily Concentrated By Region?
North America was the largest region in the vascular endothelial growth factor (VEGF) inhibitor market in 2025. Middle East is expected to be the fastest-growing region in the vascular endothelial growth factor (VEGF) inhibitor market share during the forecast period. The regions covered in the vascular endothelial growth factor (vegf) inhibitor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market 2026, By The Business Research Company
Podiatry Services Market 2026
https://www.thebusinessresearchcompany.com/report/podiatry-services-market
Diagnostic Equipment Market Report 2026
https://www.thebusinessresearchcompany.com/report/diagnostic-equipment-global-market-report
Peripheral Vascular Devices And Equipment Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
